The CANNTalks roster
‘SEPARATING THE STRAINS’ DOCUMENTARY Deejay & activist
Chelsea suffers from a type of epilepsy called ‘Juvenile Myoclonic Epilepsy’, which she has been battling since her early teenage years. Chelsea has been treating her epilepsy with Cannabidiol, having weaned herself off pharmaceutical drugs.
Co-Founder and CEO LeafCann Group
Elisabetta's journey was prompted by a childhood diagnosis of a rare and normally deadly genetic condition, which led her on a quest to understand how our bodies, medicines, nutrition and the environment interact to switch damaging genes on and off.
Dr Callie Seaman
HONORARY RESEARCHER AT SHEFFIELD HALLAM UNIVERSITY
A veteran of the hydroponic industry. Degree in Biomedical Sciences at Sheffield Hallam University, during which she worked at GlaxoSmithKline, she went on to complete a PhD on The Investigating nutrient solution for hydroponic growth of plants.
Co-founder of CannPASS, Families4Access & CANNTalks
Basia is a co-founder of Families4Access and a range of creative and cooperative initiatives in Canada, USA, and the UK. Founding Team for the Centre for Medicinal Cannabis. Creative Director for various campaigns and small organisations.
Co-founder & Director to CannPASS Research Lead to the Centre for Medicinal Cannabis
Jon spent 5 years as Political Director for United Patients Alliance, a patient-led, volunteer organisation who provide support for medical cannabis patients whilst campaigning for legal access in the UK.
FRCPSYCH, CONSULTANT PSYCHIATRIST & CLINICAL DIRECTOR / OXLEAS NHS FOUNDATION TRUST, LONDON / KING’S COLLEGE LONDON
Derek Tracy is a Consultant Psychiatrist and Clinical Director at Oxleas NHS Foundation Trust, London. His directorate is a nationally innovative integrated model encompassing adult social care, mental and physical health services.
Carly is a former Lecturer in the Arts who has a creative background that includes exhibiting at the Tate and the Saatchi gallery. After having to give up her role due to health problems, she discovered that Medical Cannabis was not only an appropriate but more effective substitute for Opioids
Chief Advocacy Officer, Canopy Growth & Founder BC Compassion Club Society, Canada’s first medical cannabis dispensary
As Chief Advocacy Officer at Canopy Growth, Hilary is responsible for patient advocacy worldwide, corporate social responsibility, and implementation of best practices for diversity & inclusion.
DM, FRCP, FRCPsych, FMedSci, DLaws Founder Chair of Drug Science
David Nutt is currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit in the Centre for Academic Psychiatry in the Division of Brain Sciences, Dept of Medicine, Hammersmith Hospital, Imperial College London. He is also visiting professor at the Open University in the UK and Maastricht University in the Netherlands.
Dr Mark Ware
Chief Medical Officer of Canopy Growth Corporation
Dr Mark Ware is currently the Chief Medical Officer of Canopy Growth Corporation. He has taken a leave of absence as Associate Professor in Family Medicine and Anaesthesia at McGill University from July 2018 to work in this capacity. He previously served as Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre for over 10 years and was the Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids since 2007.